As President and Chief Executive Officer and Board Director, Nancy Lurker leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation working with both public and private companies from start-ups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients. She has a proven track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches in a diversity of therapy areas. Lurker has served on numerous Boards across public and private companies, and advocacy organizations. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.
Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations. Mr. Elston most recently served as Chief Financial Officer and Head of Corporate Development at Enzyvant Therapeutics where he helped build the pre-commercial rare disease firm leading to its recent acquisition. He previously was President and Chief Executive Officer at 2X Oncology, Inc., where he advanced the Company from a spin-out into a multi-program, clinical-stage organization. He has also held senior executive roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers. He earned his B.B.A. in accounting from Pace University and is a Certified Public Accountant. He currently serves as a Trustee and Audit Committee Chairman of the DWS – DBX ETF Trust.
Ron Honig, Esq. has served as EyePoint's Senior Vice President, General Counsel and Company Secretary since November 2018, and Chief Legal Officer and Company Secretary since April 2021. Mr. Honig brings to EyePoint more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing and legal services industries. As lead in-house counsel to publicly-traded companies and private equity portfolio companies in the global healthcare industry, Mr. Honig has managed legal and compliance functions and has had responsibility with a wide variety of business transactions.
Most recently, Mr. Honig served as VP, Global Legal Affairs for Novanta Inc., a publicly-traded company that develops and manufactures technology solutions for medical device and advanced industrial equipment makers worldwide. Prior to Novanta, he was the Senior Vice President, General Counsel & Company Secretary of Lake Region Medical, a privately-held medical device and medical component manufacturer, where he was responsible for all legal, intellectual property and environmental, health and safety functions worldwide. In addition, Mr. Honig served as Vice President, Group Legal Affairs and Company Secretary for Gyrus ACMI, a publicly-traded medical device manufacturer focused on urological and gynecological endoscopes, digital visualization and endoscopic treatment and delivery modalities.
In addition to his in-house legal experience, Mr. Honig previously served as a corporate attorney for several law firms, including Mintz Levin Cohn Ferris Glovsky and Popeo in Boston. He earned his Juris Doctor degree from Boston University, where he served as Editor-In-Chief of the Boston University Law Review, and earned a Bachelor of Science in Finance from the Wharton School and a Bachelor of Applied Science in Systems Engineering from the School of Engineering at the University of Pennsylvania.
Ms. Leonard currently serves as the Chief People Officer and SVP, IT. She brings to EyePoint over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management and culture development experience. Most recently Ms. Leonard served as the Head of HR, Consumer Healthcare and Global Functions for Sanofi, US. From 2012 to 2015, Ms. Leonard served as the Senior Vice President of HR & IT of PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc.
Ms. Leonard has led, managed, mentored and coached individuals and teams to achieve outstanding business results. She has designed and implemented organizational development solutions at companies to increase corporate employee engagement and people effectiveness. She has led numerous M&A activities and resulting culture change and personnel integration activities.
Ms. Leonard’s experiences include work with global companies such as Novartis, Pharmacia/Pfizer, Boston Scientific Corporation, Biovail Pharmaceuticals and Silicon Graphics (SGI). Ms. Leonard also established and developed her own company, ImpactHR, LLC which provided coaching and consulting services to the life sciences sector.
Ms. Leonard holds a Masters Degree in Organizational Development and Human Resources from The University of San Francisco, and a B. A. in Psychology and Business Administration from The University of California at Los Angeles (UCLA.) Ms. Leonard is a Certified Professional Coach and has earned her Associate Certified Coach (ACC) from the International Coaching Federation (ICF.) She is also certified in the Hogan Assessment Certified Consultant.
Dr. Paggiarino joined EyePoint Pharmaceuticals from Lpath, a leader in lipid-targeted therapeutics, where he served as senior vice president and chief development officer. Prior to joining Lpath, he was vice president and therapeutic unit head for retina diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as executive director of clinical development and medical affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was clinical program director of ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Ms. Lefebvre brings over 30 years of regulatory affairs experience in pharmaceuticals, biologics, and medical devices across all phases of development. She joins EyePoint from Hengrui USA, where she served as Vice President, Head of Regulatory Science, overseeing its U.S. and E.U. regulatory strategies for their development programs.
Ms. Lefebvre has strong Ophthalmic/Ocular experience having spent nearly a decade of her career at Bausch & Lomb where she led the successful approvals of both LOTEMAX gel and VYZULTA®. She has also held prominent positions in regulatory at Valeant Pharmaceuticals, Lundbeck, and Alpharma Pharmaceuticals.
Ms. Lefebvre holds a Master’s in Regulatory Affairs from Northeastern University and a Bachelor of Science in Biochemistry from The University of Montreal.
In addition to his pharmaceutical experience, Mr. Pine began his career as an Investment Banking Financial Analyst for JP Morgan Chase. Mr. Pine has a Bachelor of Science degree from Cornell University and a Master of Business Administration degree from Columbia Business School.